Recently, we have shown that the CCL5/CCR5 axis is active in patients affected by an aggressive basal subtype of breast cancer. Using preclinical models, we have demonstrated that CCR5 promotes breast cancer invasiveness and metastatic potential, while CCR5 inhibition abrogates them. Thus, CCR5 antagonists may constitute an alternative therapeutic approach for patients affected by metastatic basal breast cancer.
Velasco-Velázquez, Marco and Pestell, Richard G, "The CCL5/CCR5 axis promotes metastasis in basal breast cancer." (2013). Kimmel Cancer Center Faculty Papers. Paper 35.